A review of the experience with pediatric written requests issued for oncology drug products.
Alemayehu Y AkaluXi MengGregory H ReamanLian MaWeishi YuanJingjing YePublished in: Pediatric blood & cancer (2020)
This provides information on requests issued in the past nearly 20 years and studies that are completed. As WRs have provided the only regulatory mechanism to assure pediatric cancer drug development, this can potentially provide insight on how pediatric cancer drug development may change in the future.